Notable Mover: Aquinox Pharmaceuticals Inc Can’t Burn Your Short Portfolio. Has Another Weak Session

Notable Mover: Aquinox Pharmaceuticals Inc Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) is a huge mover today! About 214,174 shares traded hands. Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has risen 50.86% since March 8, 2016 and is uptrending. It has outperformed by 41.54% the S&P500.
The move comes after 7 months negative chart setup for the $273.17 million company. It was reported on Oct, 11 by We have $10.67 PT which if reached, will make NASDAQ:AQXP worth $38.24 million less.

Analysts await Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) to report earnings on November, 8. They expect $-0.62 EPS, down 44.19% or $0.19 from last year’s $-0.43 per share. After $-0.63 actual EPS reported by Aquinox Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -1.59% EPS growth.

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) Ratings Coverage

Out of 5 analysts covering Aquinox Pharma (NASDAQ:AQXP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Aquinox Pharma has been the topic of 6 analyst reports since September 11, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, October 6 by Guggenheim. Jefferies maintained Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) rating on Tuesday, March 15. Jefferies has “Hold” rating and $9 price target. The stock has “Hold” rating given by Jefferies on Friday, August 5. On Friday, September 11 the stock rating was maintained by Canaccord Genuity with “Hold”. As per Friday, October 23, the company rating was initiated by Needham. The firm has “Outperform” rating given on Monday, September 21 by Leerink Swann.

According to Zacks Investment Research, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.”

More important recent Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) news were published by: which released: “Aquinox Pharmaceuticals stock skyrockets 450%” on August 07, 2015, also published article titled: “BRIEF-T. Rowe Price Associates Inc reports 14.4 pct passive stake in Aquin…”, published: “Aquinox stock rockets 2000%, Twitter goes nuts” on August 10, 2015. More interesting news about Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) was released by: and their article: “Aquinox Pharmaceuticals (AQXP) is in Overbought Territory: What’s Next?” with publication date: September 16, 2016.

AQXP Company Profile

Aquinox Pharmaceuticals, Inc., incorporated on May 25, 2007, is a clinical-stage pharmaceutical firm discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Firm operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Firm is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial investigating the ability of over 200 milligrams oral, once daily AQX-1125 to reduce pain and urinary symptoms in female patients with IC/BPS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment